{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:12:19Z","timestamp":1778271139082,"version":"3.51.4"},"reference-count":29,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bemiltenase alfa, a factor X (FX) activator derived from Daboia russelii siamensis venom, was developed as a hemostatic agent for hemophilia A and B with inhibitors (HAwI and HBwI). We conducted 2 consecutives multicenter, open-label clinical trials. The phase 1b\/2a study assessed the safety, hemostatic efficacy, and pharmacokinetic\/pharmacodynamic characteristics of bemiltenase alfa at a dose of 0.1 U\/kg. The phase 2b study further evaluated the safety and efficacy at a dose of 0.1 U\/kg. Primary efficacy end points encompassed the effective hemostasis rate, safety assessment, and antidrug antibody (ADA) development. There were 6 participants enrolled in the phase 1b study, 20 in phase 2a, and 25 in phase 2b. Patients received bemiltenase alfa for bleeding episodes in the phase 2a and 2b studies. In phase 2a, the effective hemostasis rate was 94.1% (95% confidence interval [CI], 88.7-97.4). Phase 2b showed a rate of 81.9% (95% CI, 71.0-92.9). Most adverse events were mild with grade 1 severity, with no serious events. ADA was detected in 5 patients, but no impact on efficacy and safety was found. Pharmacokinetic findings showed repeated doses of bemiltenase alfa resulted in progressive drug concentration, as indicated by the accumulation ratio index. Pharmacodynamic results indicated a reduction in activated partial thromboplastin time and an increase in thrombin generation peak. Furthermore, a mild decline in FX activity was observed postadministration. The study demonstrates FX activation as a novel hemostatic strategy, with snake venom\u2013derived bemiltenase alfa showing promising safety and efficacy for treating bleeding episodes in patients with HAwI and HBwI. These trials were registered at www.clinicaltrials.gov as #NCT05027230 and #NCT06289166.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019486","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:23:35Z","timestamp":1770236615000},"page":"3002-3010","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase 1\/2 trials"],"prefix":"10.1182","volume":"10","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[{"name":"3Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Hemostasis and Thrombosis Diagnostic Engineering Research Center of Henan Province, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruibin","family":"Huang","sequence":"additional","affiliation":[{"name":"4The First Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[{"name":"5The Second People\u2019s Hospital of Shenzhen, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panjing","family":"Wang","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeping","family":"Zhou","sequence":"additional","affiliation":[{"name":"6The Second Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1976-6415","authenticated-orcid":false,"given":"Changcheng","family":"Zheng","sequence":"additional","affiliation":[{"name":"7The First Affiliated Hospital of University of Science and Technology of China, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9041-4087","authenticated-orcid":false,"given":"Shifeng","family":"Lou","sequence":"additional","affiliation":[{"name":"8The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[{"name":"9Hematology and Oncology Research Center, Harbin First Hospital, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Song","sequence":"additional","affiliation":[{"name":"10Xi'an Central Hospital, Xi'an, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-1810","authenticated-orcid":false,"given":"Xinyue","family":"Dai","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[{"name":"11Jiangsu BioJetay Biotechnology Co, Ltd, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Tianjin Institutes of Health Science, Tianjin, China"},{"name":"12School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"suppl 6","key":"2026050815184795600_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"suppl 6","key":"2026050815184795600_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.12466","article-title":"ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective","volume":"20","author":"Oldenburg","year":"2014","journal-title":"Haemophilia"},{"key":"2026050815184795600_bib3","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating factor VIII: recent progress","volume":"10","author":"Lacroix-Desmazes","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"2026050815184795600_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.12091","article-title":"Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization","volume":"160","author":"Collins","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2026050815184795600_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0037-1612943","article-title":"The North American Immune Tolerance Registry: practices, outcomes, outcome predictors","volume":"87","author":"DiMichele","year":"2002","journal-title":"Thromb Haemost"},{"issue":"1","key":"2026050815184795600_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2006.06359.x","article-title":"Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors","volume":"136","author":"Reipert","year":"2007","journal-title":"Br J Haematol"},{"issue":"22","key":"2026050815184795600_bib7","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial","volume":"143","author":"Kenet","year":"2024","journal-title":"Blood"},{"issue":"10386","key":"2026050815184795600_bib8","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"The Lancet"},{"issue":"9","key":"2026050815184795600_bib9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2026050815184795600_bib10","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Dargaud","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"2026050815184795600_bib11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1055\/s-0037-1612626","article-title":"Inhibitors in hemophilia: treatment challenges and novel options","volume":"44","author":"Barg","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"2026050815184795600_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2026050815184795600_bib13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1538-7836.2005.01237.x","article-title":"A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI)","volume":"3","author":"Dahm","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2026050815184795600_bib14","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/jth.14296","article-title":"The future of bypassing agents for hemophilia with inhibitors in the era of novel agents","volume":"16","author":"Shapiro","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026050815184795600_bib15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bjh.17322","article-title":"Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up","volume":"192","author":"Dou","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2026050815184795600_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11239-021-02456-w","article-title":"Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics","volume":"52","author":"Camire","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"3-6","key":"2026050815184795600_bib17","first-page":"234","article-title":"Snake venom prothrombin activators homologous to blood coagulation factor XA","volume":"31","author":"Joseph","year":"2001","journal-title":"Haemostasis"},{"issue":"6","key":"2026050815184795600_bib18","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jtha.2023.02.026","article-title":"Russell's viper venom: from diagnostic to bypassing agent for hemophilia?","volume":"21","author":"Veizaj","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2026050815184795600_bib19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jtha.2023.01.040","article-title":"Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors","volume":"21","author":"Liu","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026050815184795600_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0043-1771269","article-title":"Russell viper venom: a journey from the bedside to the bench and back to the bedside","volume":"50","author":"Thachil","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"2026050815184795600_bib21","unstructured":"U.S. Food & Drug Administration\n          . Orphan Drug Designations and Approvals. Accessed 12 February 2026. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/listResult.cfm."},{"issue":"11","key":"2026050815184795600_bib22","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026050815184795600_bib23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2516.2011.02704.x","article-title":"Patient\/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the dosing observational study in hemophilia (DOSE)","volume":"18","author":"Young","year":"2012","journal-title":"Haemophilia"},{"issue":"6","key":"2026050815184795600_bib24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1365-2516.1998.00209.x","article-title":"A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group","volume":"4","author":"Lusher","year":"1998","journal-title":"Haemophilia"},{"issue":"2","key":"2026050815184795600_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2516.2007.01601.x","article-title":"Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison","volume":"14","author":"Young","year":"2008","journal-title":"Haemophilia"},{"issue":"2","key":"2026050815184795600_bib26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1538-7836.2006.01772.x","article-title":"A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors","volume":"4","author":"Santagostino","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026050815184795600_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2516.2009.02179.x","article-title":"The value of early treatment in patients with haemophilia and inhibitors","volume":"16","author":"Kavakli","year":"2010","journal-title":"Haemophilia"},{"issue":"2","key":"2026050815184795600_bib28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven comparative (FENOC) study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2026050815184795600_bib29","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ajh.24811","article-title":"Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: a review of clinical studies and registries","volume":"92","author":"Young","year":"2017","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3002\/2515929\/blooda_adv-2025-019486-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3002\/2515929\/blooda_adv-2025-019486-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:18:56Z","timestamp":1778267936000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3002\/566429\/A-specific-FX-activator-for-bleeding-treatment-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019486","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,4,30]]}}}